BidaskClub upgraded shares of Natus Medical (NASDAQ:BABY) from a sell rating to a hold rating in a research note published on Saturday.
BABY has been the topic of several other reports. Roth Capital set a $39.00 price objective on shares of Natus Medical and gave the company a buy rating in a report on Tuesday, February 27th. Zacks Investment Research lowered shares of Natus Medical from a buy rating to a hold rating in a report on Tuesday, December 26th. William Blair lowered shares of Natus Medical from an outperform rating to a market perform rating in a report on Monday, January 8th. Finally, Benchmark restated a buy rating and issued a $49.00 target price (down from $55.00) on shares of Natus Medical in a research note on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $44.33.
Natus Medical (NASDAQ:BABY) opened at $33.80 on Friday. The stock has a market cap of $1,105.90, a P/E ratio of -54.52 and a beta of 0.55. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.54 and a current ratio of 3.32. Natus Medical has a 1-year low of $28.00 and a 1-year high of $43.60.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, February 7th. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.54 by ($0.12). The business had revenue of $131.40 million for the quarter, compared to analysts’ expectations of $131.38 million. Natus Medical had a negative net margin of 4.05% and a positive return on equity of 11.36%. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.51 earnings per share. equities analysts predict that Natus Medical will post 1.63 EPS for the current year.
Natus Medical announced that its Board of Directors has authorized a stock buyback plan on Thursday, February 22nd that permits the company to repurchase $30.00 million in shares. This repurchase authorization permits the medical equipment provider to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.
In other Natus Medical news, Director Ken Ludlum sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $31.68, for a total value of $126,720.00. Following the completion of the sale, the director now directly owns 93,825 shares in the company, valued at $2,972,376. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.50% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. American International Group Inc. boosted its stake in Natus Medical by 5.7% in the third quarter. American International Group Inc. now owns 25,767 shares of the medical equipment provider’s stock valued at $966,000 after acquiring an additional 1,398 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in Natus Medical by 11.5% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 14,044 shares of the medical equipment provider’s stock valued at $527,000 after acquiring an additional 1,452 shares in the last quarter. Rhumbline Advisers boosted its stake in Natus Medical by 2.5% in the third quarter. Rhumbline Advisers now owns 67,065 shares of the medical equipment provider’s stock valued at $2,515,000 after acquiring an additional 1,620 shares in the last quarter. LPL Financial LLC lifted its stake in shares of Natus Medical by 24.9% during the fourth quarter. LPL Financial LLC now owns 10,553 shares of the medical equipment provider’s stock worth $403,000 after buying an additional 2,103 shares during the period. Finally, Swiss National Bank lifted its stake in shares of Natus Medical by 4.4% during the fourth quarter. Swiss National Bank now owns 56,500 shares of the medical equipment provider’s stock worth $2,158,000 after buying an additional 2,400 shares during the period. Institutional investors own 95.76% of the company’s stock.
WARNING: This story was originally published by Stock Observer and is owned by of Stock Observer. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.thestockobserver.com/2018/03/21/natus-medical-baby-upgraded-to-hold-at-bidaskclub.html.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.